TUXEDO: A phase I/II trial of cetuximab with chemoradiotherapy in muscle-invasive bladder cancer

Keyphrases

• Phase II Trial 100%
• Chemoradiotherapy 100%
• Muscle-invasive Bladder Cancer 100%
• Cetuximab 100%
• Performance Status 33%
• Local Control 33%
• Clinical Evaluation 16%
• Mitomycin C 16%
• 5-fluorouracil (5-FU) 16%
• Neoadjuvant Therapy 16%
• Radiotherapy 16%
• Adverse Effects 16%
• Serious Adverse Events 16%
• Urothelial Cancer 16%
• Patient-completed 16%
• Delay Reduction 16%
• Treatment Toxicity 16%
• Neoadjuvant Chemotherapy 16%
• Radiotherapy Treatment 16%
• Radiotherapy Planning 16%
• Treatment Completion 16%
• UK Hospitals 16%
• Accruals 16%
• Dose Reduction 16%
• Loading Dose 16%
• Initial Loading 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemoradiation Therapy 100%
• Muscle Invasive Bladder Cancer 100%
• Cetuximab 100%
• Malignant Neoplasm 16%
• Clinical Trial 16%
• Adverse Event 16%
• Fluorouracil 16%
• Mitomycin 16%
• Chemotherapy 16%